Market
Company making largest biotech acquisition by end of 2025?
2
Resolution / Starting Odds
Johnson & Johnson • 25%
Eli Lilly • 25%
GSK • 25%
Other • 25%
Official announcements from the companies, financial news outlets
Story
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion at $132 Per Share, Marking Largest Biotech Deal in Over a Year
Jan 13, 2025, 02:49 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc. for approximately $14.6 billion, marking the largest biotech deal in over a year. The acquisition, announced at the J.P. Morgan Healthcare Conference, involves a purchase price of $132 per share. Intra-Cellular, co-founded by Sharon Mates in 2002, is known for its drug Caplyta, which received FDA approval in December 2019. The deal comes amidst a flurry of biotech acquisitions, with Eli Lilly and GSK also announcing significant purchases of Scorpion Therapeutics and IDRx, respectively, during the same conference.
View original story
Similar markets
Biogen • 25%
Vertex Pharmaceuticals • 25%
Other Biopharma Companies • 25%
Gilead Sciences • 25%
Stoke Therapeutics • 25%
Multiple companies • 25%
Another named biotech company • 25%
No further acquisitions • 25%
Successful acquisition of another biotech • 25%
Successful acquisition of Sage Therapeutics • 25%
No acquisitions completed • 25%
Multiple acquisitions completed • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
AstraZeneca • 25%
Roche • 25%
Pfizer • 25%
Daiichi Sankyo • 25%
Other • 25%
AstraZeneca • 25%
Biogen • 25%
Gilead Sciences • 25%
Roche • 25%
Pfizer • 25%
Novartis • 25%
Other • 25%
A company with late-stage drug development • 25%
Sage Therapeutics • 25%
A company with a marketed drug • 25%
A company with mid-stage drug development • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%